LLY up +0.74% percent Today $LLY High is at 68.04
Post# of 128
Posted On: 11/13/2014 2:42:25 PM
LLY up +0.74% percent Today $LLY High is at 68.04 and the Low 67.56 with current volume of 418,916.
Recent News posted below.
Eli Lilly and Company LLY other info.
http://investorshangout.com/Eli-Lilly--Co-LLY-51689/
LLY Eli Lilly and Company Recent Headline News
Global Insulin Delivery Devices Market Outlook 2018
M2 - Thu Nov 13, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttg7ws/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. In 2013, a total of 382 Million People had diabetes and by 2030 this number is expected to rise to 552 Million. This finding by the International Diabetes Federation (IDF) and similar results from studies done by organizations of repute such as WHO, CDC, NHS, etc., suggest that a huge patient population exists in the diabetes market. In 2013, health expenditure on diabetes accounted for around 10% of the total health expenditure globally. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In this latest research study Global Insulin Delivery Devices Market Outlook 2018, the analysts identified the market dynamics in various important regions to highlight the areas offering promising opportunities to companies for boosting their growth. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of the delivery devices market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth, and the future outlook of the segments. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players Companies Mentioned: - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/tt...al_insulin
JNJ: 108.72 (-0.03), ABT: 44.39 (+0.16), PODD: 45.79 (-0.61), NVO: 43.99 (-0.33), MDT: 69.21 (+0.71), LLY: 67.46 (+0.06)
Acute Coronary Syndrome: Global Drug Forecast and Market Analysis to 2023 - Market to Triple from $12.3 Billion in 2013 to $43.4 Billion by 2023
M2 - Thu Nov 13, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/mhkp4w/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023" report to their offering. New Blockbuster Drugs to More than Triple Acute Coronary Syndrome Treatment Market Value by 2023 The launch of several drugs with extraordinary blockbuster potential will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023 This report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape. Amgen's evolocumab, Sanofi and Regeneron's alirocumab, and Pfizer's bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and The authors expects these treatments to be launched in the middle of the forecast period. Eric J. Dimise, Ph.D., The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment. The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion. The authors has also identified two new anticoagulants, Janssen's Xarelto and Merck's Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years. Dimise states: Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018. When added to the drug's mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015. The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential, concludes the analyst. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/mh...harmapoint
JNJ: 108.72 (-0.03), MRK: 59.30 (-0.01), AMGN: 160.35 (-1.58), LLY: 67.46 (+0.06), GSK: 45.59 (-0.03), BMY: 57.50 (-1.11)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.07 (+0.43), AGN: 196.06 (-0.45), HLF: 37.96 (+0.15), VRX: 131.42 (+0.33), PFE: 30.33 (-0.09), MRK: 59.30 (-0.01), LLY: 67.46 (+0.06)
Global Human Growth Hormone Drugs Industry
PR Newswire - Tue Nov 11, 1:17PM CST
This report analyzes the worldwide markets for Human Growth Hormone Drugs in US$ Million by the following Brands: Humatrope, Norditropin, Genotropin, Nutropin, Saizen, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as -
LLY: 67.46 (+0.06)
Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 11:52AM CST
Aegerion Pharmaceuticals, Inc. (AEGR) has signed an agreement with AstraZeneca to acquire the latter's Myalept for $325 million.
BIIB: 315.56 (-5.46), AZN: 74.51 (+0.25), LLY: 67.46 (+0.06), AEGR: 20.53 (-0.78), GSK: 45.59 (-0.03)
Research and Markets: Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
Business Wire - Tue Nov 11, 9:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjsnd9/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering.
LLY: 67.46 (+0.06)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.72 (-0.03), PFE: 30.33 (-0.09), MRK: 59.30 (-0.01), AZN: 74.51 (+0.25), LLY: 67.46 (+0.06), GSK: 45.59 (-0.03)
UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:30PM CST
UCB SA (UCBJF) entered into an agreement with Advent International and Avista Capital Partners for the sale of its specialty generics subsidiary for $1.525 billion.
LCI: 48.34 (-1.39), LLY: 67.46 (+0.06), GSK: 45.59 (-0.03), NVS: 94.18 (+1.52)
Look for Shares of Eli Lilly to Potentially Pullback after Yesterday's 2.63% Rise
Comtex SmarTrend(R) - Mon Nov 10, 3:59PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $66.42 to a high of $68.42. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $67.61 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 67.46 (+0.06)
Eli Lilly Rises 2.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Nov 10, 3:59PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $66.42 to a high of $68.42. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $67.61 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 67.46 (+0.06)
Earnings Look Back: Eli Lilly Is Up 3.5% Since Reporting Quarterly Results 2 Weeks Ago (LLY)
Comtex SmarTrend(R) - Mon Nov 10, 11:31AM CST
Two weeks ago on October 23rd, 2014 Eli Lilly (NYSE:LLY) reported earnings and analysts, on average, expected earnings of $0.67 on sales of $4.8 billion. The company actually reported EPS of $0.66 on sales of $4.9 billion, missing EPS estimates by $0.01 and beating revenue estimates by $37.8 million. Since the company's report, shares of Eli Lilly have risen from $64.35 to $66.60, representing a gain of 3.5% in the past 18 days.
LLY: 67.46 (+0.06)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.92 (unch), CRIS: 1.29 (-0.01), IMMU: 3.79 (-0.10), PCYC: 137.00 (-0.37), ONCY: 0.80 (-0.04), PFE: 30.33 (-0.09), LLY: 67.46 (+0.06), BMY: 57.50 (-1.11), GSK: 45.59 (-0.03), JNJ: 108.72 (-0.03), SNTA: 3.23 (-0.13), NVS: 94.18 (+1.52), XLRN: 37.62 (+3.83), ARRY: 3.71 (-0.10), CELGZ: 3.14 (+0.01), EXEL: 1.78 (-0.03)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 15.48 (-1.73), LLY: 67.46 (+0.06), CNCE: 13.44 (+0.61), OPK: 8.33 (-0.04), AZN: 74.51 (+0.25), ALXN: 192.00 (-1.69), ICPT: 159.97 (-2.99), NPSP: 29.63 (+0.46), XLRN: 37.62 (+3.83)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.61 (-0.03), IMGN: 9.75 (-0.37), AMGN: 160.35 (-1.58), LLY: 67.46 (+0.06), ONTX: 4.70 (-0.15), BMY: 57.50 (-1.11), GSK: 45.59 (-0.03), OXGN: 1.76 (+0.01), XLRN: 37.62 (+3.83), KPTI: 40.55 (-1.86), NVS: 94.18 (+1.52)
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020
M2 - Mon Nov 10, 10:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/pwsnhg/major_depressive) has announced the addition of the "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020" report to their offering. The global market for Major Depressive Disorder (MDD) therapeutics was valued at $8.7 billion in 2013, and several key patent expiries will cause it to decline at a negative Compound Annual Growth Rate (CAGR) of 4% to $7.4 billion by 2017. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period. New drug launches after 2017 will reinvigorate the market, which will increase at a CAGR of 3.5% to $8.1 billion by 2020 Scope: - A brief introduction to MDD, including the disease's pathophysiology, etiology, diagnosis and treatment algorithms. - In-depth analysis of currently marketed drugs for MDD, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy - A comprehensive review of the pipeline for MDD, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets - Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type. - Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. - Discussion of the drivers and barriers for market growth. - In-depth analysis of all licensing and co-development deals that have occurred in the MDD market since 2006. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products Therapeutic Landscape - Lexapro/Cipralex (escitalopram) - Lundbeck/Forest Laboratories - Viibryd (vilazodone) - Forest (Actavis) - Cymbalta (duloxetine) - Eli Lilly - Pristiq (desvenlafaxine) - Pfizer - Seroquel XR (quetiapine) - AstraZeneca - Brintellix (vortioxetine) - Takeda and Lundbeck - Abilify (aripiprazole) - Otsuka Comparative Efficacy and Safety 4 Major Depressive Disorder Market to 2020 - Pipeline Products Overall Pipeline Pipeline Analysis by Molecule Type Pipeline Analysis by Mechanism of Action Clinical Trials - Failure Rate - Patient Enrollment and Clinical Trial Size - Duration Promising Drug Candidates in the Pipeline - OPC-34712 (brexpiprazole) - Otsuka and Lundbeck - ALKS-5461 - Alkermes - Amitifadine (EB-1010) - Euthymics Bioscience 5 Market Forecast to 2020 Geographical Markets Drivers and Barriers 6 Deals and Strategic Consolidations Major Licensing Deals - Ranbaxy Pharma Enters into Licensing Agreement with Alembic Pharma for desvenlafaxine Base Extended-Release Tablets - Forest Labs Enters into Licensing Agreement with Moksha8 for Viibryd - AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept - Impax Labs Enters into Licensing Agreement with Wyeth Major Co-development Deals - Lundbeck Enters into Co-Development Agreement with Otsuka Pharma - Azaya Lundbeck Enters into Co-Development Agreement with Takeda 7 Appendix For more information visit http://www.researchandmarkets.com/research/pw...depressive
LLY: 67.46 (+0.06), ALKS: 52.73 (-0.27)
Lilly's Trulicity(TM) (dulaglutide) Now Available in U.S. Pharmacies
PR Newswire - Mon Nov 10, 9:00AM CST
The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's (NYSE: LLY) Trulicity(TM) (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind. It comes in a single-dose pen and does not require the patient to mix, measure, or handle the needle.
LLY: 67.46 (+0.06)
Stock Picking Grades For All Cap Blend Style Fund Managers
David Trainer - Seeking Alpha - Mon Nov 10, 8:30AM CST
This report shows how well All Cap Blend ETFs and mutual fund managers pick stocks. We juxtapose our Portfolio Management Rating on funds, which grades managers based on the quality of the stocks they choose, with the number of good stocks...
DGRW: 30.45 (-0.04), LLY: 67.46 (+0.06), SHLD: 38.29 (+0.53), PRFZ: 99.31 (-1.07)
Is this MannKind Corporation's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 10, 7:32AM CST
The commercial success or failure of a new drug is rarely the result of a single event. So, predicting how a drug will perform prior to launch is perhaps more guesswork than most experts will openly admit. For example, after an arduous back and forth...
LLY: 67.46 (+0.06), GSK: 45.59 (-0.03), MNKD: 6.28 (+0.20), NVS: 94.18 (+1.52)
MannKind Is On The Mend
Nicholas Kitonyi - at Seeking Alpha - Fri Nov 07, 6:07PM CST
NVO: 43.99 (-0.33), PFE: 30.34 (-0.08), LLY: 67.46 (+0.06), MNKD: 6.28 (+0.20), SNY: 46.50 (-0.06)
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.40 (-0.15), MNK: 86.92 (-6.07), BAX: 72.08 (+0.75), LLY: 67.46 (+0.06)
Recent News posted below.
Eli Lilly and Company LLY other info.
http://investorshangout.com/Eli-Lilly--Co-LLY-51689/
LLY Eli Lilly and Company Recent Headline News
Global Insulin Delivery Devices Market Outlook 2018
M2 - Thu Nov 13, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttg7ws/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. In 2013, a total of 382 Million People had diabetes and by 2030 this number is expected to rise to 552 Million. This finding by the International Diabetes Federation (IDF) and similar results from studies done by organizations of repute such as WHO, CDC, NHS, etc., suggest that a huge patient population exists in the diabetes market. In 2013, health expenditure on diabetes accounted for around 10% of the total health expenditure globally. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In this latest research study Global Insulin Delivery Devices Market Outlook 2018, the analysts identified the market dynamics in various important regions to highlight the areas offering promising opportunities to companies for boosting their growth. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of the delivery devices market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth, and the future outlook of the segments. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players Companies Mentioned: - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/tt...al_insulin
JNJ: 108.72 (-0.03), ABT: 44.39 (+0.16), PODD: 45.79 (-0.61), NVO: 43.99 (-0.33), MDT: 69.21 (+0.71), LLY: 67.46 (+0.06)
Acute Coronary Syndrome: Global Drug Forecast and Market Analysis to 2023 - Market to Triple from $12.3 Billion in 2013 to $43.4 Billion by 2023
M2 - Thu Nov 13, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/mhkp4w/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023" report to their offering. New Blockbuster Drugs to More than Triple Acute Coronary Syndrome Treatment Market Value by 2023 The launch of several drugs with extraordinary blockbuster potential will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023 This report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape. Amgen's evolocumab, Sanofi and Regeneron's alirocumab, and Pfizer's bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and The authors expects these treatments to be launched in the middle of the forecast period. Eric J. Dimise, Ph.D., The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment. The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion. The authors has also identified two new anticoagulants, Janssen's Xarelto and Merck's Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years. Dimise states: Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018. When added to the drug's mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015. The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential, concludes the analyst. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/mh...harmapoint
JNJ: 108.72 (-0.03), MRK: 59.30 (-0.01), AMGN: 160.35 (-1.58), LLY: 67.46 (+0.06), GSK: 45.59 (-0.03), BMY: 57.50 (-1.11)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.07 (+0.43), AGN: 196.06 (-0.45), HLF: 37.96 (+0.15), VRX: 131.42 (+0.33), PFE: 30.33 (-0.09), MRK: 59.30 (-0.01), LLY: 67.46 (+0.06)
Global Human Growth Hormone Drugs Industry
PR Newswire - Tue Nov 11, 1:17PM CST
This report analyzes the worldwide markets for Human Growth Hormone Drugs in US$ Million by the following Brands: Humatrope, Norditropin, Genotropin, Nutropin, Saizen, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as -
LLY: 67.46 (+0.06)
Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 11:52AM CST
Aegerion Pharmaceuticals, Inc. (AEGR) has signed an agreement with AstraZeneca to acquire the latter's Myalept for $325 million.
BIIB: 315.56 (-5.46), AZN: 74.51 (+0.25), LLY: 67.46 (+0.06), AEGR: 20.53 (-0.78), GSK: 45.59 (-0.03)
Research and Markets: Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
Business Wire - Tue Nov 11, 9:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjsnd9/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering.
LLY: 67.46 (+0.06)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.72 (-0.03), PFE: 30.33 (-0.09), MRK: 59.30 (-0.01), AZN: 74.51 (+0.25), LLY: 67.46 (+0.06), GSK: 45.59 (-0.03)
UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:30PM CST
UCB SA (UCBJF) entered into an agreement with Advent International and Avista Capital Partners for the sale of its specialty generics subsidiary for $1.525 billion.
LCI: 48.34 (-1.39), LLY: 67.46 (+0.06), GSK: 45.59 (-0.03), NVS: 94.18 (+1.52)
Look for Shares of Eli Lilly to Potentially Pullback after Yesterday's 2.63% Rise
Comtex SmarTrend(R) - Mon Nov 10, 3:59PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $66.42 to a high of $68.42. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $67.61 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 67.46 (+0.06)
Eli Lilly Rises 2.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Nov 10, 3:59PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $66.42 to a high of $68.42. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $67.61 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 67.46 (+0.06)
Earnings Look Back: Eli Lilly Is Up 3.5% Since Reporting Quarterly Results 2 Weeks Ago (LLY)
Comtex SmarTrend(R) - Mon Nov 10, 11:31AM CST
Two weeks ago on October 23rd, 2014 Eli Lilly (NYSE:LLY) reported earnings and analysts, on average, expected earnings of $0.67 on sales of $4.8 billion. The company actually reported EPS of $0.66 on sales of $4.9 billion, missing EPS estimates by $0.01 and beating revenue estimates by $37.8 million. Since the company's report, shares of Eli Lilly have risen from $64.35 to $66.60, representing a gain of 3.5% in the past 18 days.
LLY: 67.46 (+0.06)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.92 (unch), CRIS: 1.29 (-0.01), IMMU: 3.79 (-0.10), PCYC: 137.00 (-0.37), ONCY: 0.80 (-0.04), PFE: 30.33 (-0.09), LLY: 67.46 (+0.06), BMY: 57.50 (-1.11), GSK: 45.59 (-0.03), JNJ: 108.72 (-0.03), SNTA: 3.23 (-0.13), NVS: 94.18 (+1.52), XLRN: 37.62 (+3.83), ARRY: 3.71 (-0.10), CELGZ: 3.14 (+0.01), EXEL: 1.78 (-0.03)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 15.48 (-1.73), LLY: 67.46 (+0.06), CNCE: 13.44 (+0.61), OPK: 8.33 (-0.04), AZN: 74.51 (+0.25), ALXN: 192.00 (-1.69), ICPT: 159.97 (-2.99), NPSP: 29.63 (+0.46), XLRN: 37.62 (+3.83)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.61 (-0.03), IMGN: 9.75 (-0.37), AMGN: 160.35 (-1.58), LLY: 67.46 (+0.06), ONTX: 4.70 (-0.15), BMY: 57.50 (-1.11), GSK: 45.59 (-0.03), OXGN: 1.76 (+0.01), XLRN: 37.62 (+3.83), KPTI: 40.55 (-1.86), NVS: 94.18 (+1.52)
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020
M2 - Mon Nov 10, 10:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/pwsnhg/major_depressive) has announced the addition of the "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020" report to their offering. The global market for Major Depressive Disorder (MDD) therapeutics was valued at $8.7 billion in 2013, and several key patent expiries will cause it to decline at a negative Compound Annual Growth Rate (CAGR) of 4% to $7.4 billion by 2017. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period. New drug launches after 2017 will reinvigorate the market, which will increase at a CAGR of 3.5% to $8.1 billion by 2020 Scope: - A brief introduction to MDD, including the disease's pathophysiology, etiology, diagnosis and treatment algorithms. - In-depth analysis of currently marketed drugs for MDD, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy - A comprehensive review of the pipeline for MDD, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets - Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type. - Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. - Discussion of the drivers and barriers for market growth. - In-depth analysis of all licensing and co-development deals that have occurred in the MDD market since 2006. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products Therapeutic Landscape - Lexapro/Cipralex (escitalopram) - Lundbeck/Forest Laboratories - Viibryd (vilazodone) - Forest (Actavis) - Cymbalta (duloxetine) - Eli Lilly - Pristiq (desvenlafaxine) - Pfizer - Seroquel XR (quetiapine) - AstraZeneca - Brintellix (vortioxetine) - Takeda and Lundbeck - Abilify (aripiprazole) - Otsuka Comparative Efficacy and Safety 4 Major Depressive Disorder Market to 2020 - Pipeline Products Overall Pipeline Pipeline Analysis by Molecule Type Pipeline Analysis by Mechanism of Action Clinical Trials - Failure Rate - Patient Enrollment and Clinical Trial Size - Duration Promising Drug Candidates in the Pipeline - OPC-34712 (brexpiprazole) - Otsuka and Lundbeck - ALKS-5461 - Alkermes - Amitifadine (EB-1010) - Euthymics Bioscience 5 Market Forecast to 2020 Geographical Markets Drivers and Barriers 6 Deals and Strategic Consolidations Major Licensing Deals - Ranbaxy Pharma Enters into Licensing Agreement with Alembic Pharma for desvenlafaxine Base Extended-Release Tablets - Forest Labs Enters into Licensing Agreement with Moksha8 for Viibryd - AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept - Impax Labs Enters into Licensing Agreement with Wyeth Major Co-development Deals - Lundbeck Enters into Co-Development Agreement with Otsuka Pharma - Azaya Lundbeck Enters into Co-Development Agreement with Takeda 7 Appendix For more information visit http://www.researchandmarkets.com/research/pw...depressive
LLY: 67.46 (+0.06), ALKS: 52.73 (-0.27)
Lilly's Trulicity(TM) (dulaglutide) Now Available in U.S. Pharmacies
PR Newswire - Mon Nov 10, 9:00AM CST
The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's (NYSE: LLY) Trulicity(TM) (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind. It comes in a single-dose pen and does not require the patient to mix, measure, or handle the needle.
LLY: 67.46 (+0.06)
Stock Picking Grades For All Cap Blend Style Fund Managers
David Trainer - Seeking Alpha - Mon Nov 10, 8:30AM CST
This report shows how well All Cap Blend ETFs and mutual fund managers pick stocks. We juxtapose our Portfolio Management Rating on funds, which grades managers based on the quality of the stocks they choose, with the number of good stocks...
DGRW: 30.45 (-0.04), LLY: 67.46 (+0.06), SHLD: 38.29 (+0.53), PRFZ: 99.31 (-1.07)
Is this MannKind Corporation's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 10, 7:32AM CST
The commercial success or failure of a new drug is rarely the result of a single event. So, predicting how a drug will perform prior to launch is perhaps more guesswork than most experts will openly admit. For example, after an arduous back and forth...
LLY: 67.46 (+0.06), GSK: 45.59 (-0.03), MNKD: 6.28 (+0.20), NVS: 94.18 (+1.52)
MannKind Is On The Mend
Nicholas Kitonyi - at Seeking Alpha - Fri Nov 07, 6:07PM CST
NVO: 43.99 (-0.33), PFE: 30.34 (-0.08), LLY: 67.46 (+0.06), MNKD: 6.28 (+0.20), SNY: 46.50 (-0.06)
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.40 (-0.15), MNK: 86.92 (-6.07), BAX: 72.08 (+0.75), LLY: 67.46 (+0.06)
(0)
(0)Eli Lilly & Co. (LLY) Stock Research Links
Scroll down for more posts ▼